Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...